![]() |
|
|
Vol. 289, Issue 2, 807-815, May 1999
British Columbia Cancer Agency, Division of Medical Oncology,
Section of Advanced Therapeutics (D.L.R., S.K., E.K.W., M.B.B.),
Vancouver, British Columbia, Canada; and
Inex Pharmaceuticals Inc.
(M.M., P.T.), Burnaby, British Columbia, Canada
The transfer of plasmid expression vectors to cells is essential
for transfection after administration of lipid-based DNA formulations
(lipoplexes). A murine i.p. B16/BL6 tumor model was used to
characterize DNA delivery, liposomal lipid delivery, and gene transfer
after regional (i.p.) administration of free plasmid DNA and DNA
lipoplexes. DNA lipoplexes were prepared using cationic dioleoyldimethylammonium
chloride/dioleoylphosphatidylethanolamine (50:50 mol ratio)
liposomes mixed with plasmid DNA (1 µg DNA/10 nmol lipid). The
plasmid used contained the chloramphenicol acetyltransferase gene and
chloramphenicol acetyltransferase expression (mU/g tumor) was measured
to estimate transfection efficiency. Tumor-associated DNA and liposomal
lipid levels were measured to estimate the efficiency of lipid-mediated
DNA delivery to tumors. Plasmid DNA delivery was estimated using
[3H]-labeled plasmid as a tracer, dot blot analysis, and/or Southern
analysis. Liposomal lipid delivery was estimated using
[14C]-dioleoylphosphatidylethanolamine as a
liposomal lipid marker. Gene expression in the B16/BL6 tumors was
highly variable, with values ranging from greater than 2,000 mU/g tumor
to less than 100 mU/g tumor. There was a tendency to observe enhanced
transfection in small (<250 mg) tumors. Approximately 18% of the
injected dose of DNA was associated with these small tumors 2 h
after i.p. administration. Southern analysis of extracted tumor DNA
indicated that plasmid DNA associated with tumors was intact 24 h
after administration. DNA and associated liposomal lipid are
efficiently bound to tumors after regional administration; however, it
is unclear whether delivery is sufficient to abet internalization and
appropriate subcellular localization of the expression vector.
This article has been cited by other articles:
![]() |
H. M. Horton, O. Dorigo, P. Hernandez, D. Anderson, J. S. Berek, and S. E. Parker IL-2 Plasmid Therapy of Murine Ovarian Carcinoma Inhibits the Growth of Tumor Ascites and Alters Its Cytokine Profile J. Immunol., December 15, 1999; 163(12): 6378 - 6385. [Abstract] [Full Text] [PDF] |
||||